1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). - Eminowicz, G.; Alexandre, J.; Sanchez, L.M. Manso; Braicu, I.; Madry, R.; Taskiran, C.; Farolfi, A.; Vulsteke, C.; Hasegawa, K.; Wang, J.; Kim, J-W.; Ananda, S.; et al. (Annals of Oncology, 2025)